Company Filing History:
Years Active: 1998-2009
Title: Innovations by Philip M. Wallace in Immunology
Introduction
Philip M. Wallace is an esteemed inventor based in Seattle, WA, known for his significant contributions to the field of immunology. With a total of five patents to his name, his work focuses on innovative approaches to enhance immune responses and T cell interactions. His research plays a crucial role in advancing treatments for various autoimmune diseases and improving immunotherapy strategies.
Latest Patents
Among his latest patents, Wallace has developed inventions related to soluble CTLA4 mutant molecules. One of his notable patents identifies the CTLA4 receptor as a ligand for the B7 antigen. This invention includes the complete amino acid sequence encoding the human CTLA4 receptor gene and offers methods for expressing CTLA4 as an immunoglobulin fusion protein. It further details the preparation of hybrid CTLA4 fusion proteins and the application of soluble fusion proteins, fragments, and derivatives, including monoclonal antibodies reactive with B7 and CTLA4. These innovations aim to regulate T cell interactions and the immune responses that stem from these interactions. Additionally, he has patented soluble CTLA4 mutant molecules that bind to CD80 and/or CD86 antigens, broadening the understanding of immune modulation.
Career Highlights
Philip M. Wallace is affiliated with Bristol-Myers Squibb Company, a leading biopharmaceutical firm that aids in the development of innovative medicines. His work within the company has been instrumental in translating complex immunological research into practical applications that can benefit patients.
Collaborations
Throughout his career, Wallace has collaborated with notable professionals in the field, including Jeffrey A. Ledbetter and Nitin Krishnaji Damle. These partnerships have fostered a collaborative environment that enriches the research community and enhances the capabilities of immunotherapy treatments.
Conclusion
Philip M. Wallace’s innovations, particularly in the area of soluble CTLA4 mutant molecules, underscore his role as a pioneer in immunological research. His contributions have not only advanced scientific understanding but also paved the way for potential breakthroughs in treating immune-related disorders. As he continues his work at Bristol-Myers Squibb Company, the impact of his inventions will undoubtedly further influence the future of immunotherapy and patient care.